{"id":"W1808718376","doi":"10.6004/jnccn.2013.0217","title":"Emerging Treatments in Recurrent and Metastatic Colorectal Cancer","year":2013,"lang":"en","type":"review","venue":"Journal of the National Comprehensive Cancer Network","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Sanofi; Bayer HealthCare; Regeneron Pharmaceuticals; Amgen; Pfizer; Oncolytics Biotech; Eli Lilly and Company; Bristol-Myers Squibb; Genentech; Bayer","keywords":"Medicine; Bevacizumab; Cetuximab; Regorafenib; Panitumumab; Colorectal cancer; Aflibercept; Oncology; Chemotherapy; Targeted therapy; Epidermal growth factor receptor; Internal medicine; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000112541,0.0003879668,0.001819562,0.0001893169,0.0001326796,0.00002726088,0.00014957,0.00008528445,0.0001164885],"category_scores_gemma":[0.0000577897,0.0002107376,0.0005234723,0.0005234332,0.00009481205,0.00007697931,0.0001200071,0.0005555716,0.000002199481],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001716798,"about_ca_system_score_gemma":0.0008870944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007558478,"about_ca_topic_score_gemma":0.00009847797,"domain_scores_codex":[0.997834,0.0001903444,0.000831212,0.0002352028,0.0006379054,0.0002713581],"domain_scores_gemma":[0.9975765,0.000366979,0.001062368,0.00007267157,0.0008166432,0.0001048363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002487463,0.0001601898,0.001177619,0.002195744,0.004620782,0.00003538842,0.0001813513,0.0003904116,0.000001253788,0.00002822809,0.01715399,0.9738063],"study_design_scores_gemma":[0.001714133,0.0003695328,0.008295878,0.02246809,0.003777358,0.0002894176,0.00004638064,0.00005740231,9.081857e-7,0.0002306538,0.9625199,0.0002303438],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00234349,0.9942875,4.80037e-7,0.0005253015,0.001567197,0.001032874,0.0000634512,0.000004133284,0.0001755649],"genre_scores_gemma":[0.0006255849,0.9973164,0.0001335481,0.0002468424,0.001061611,0.0003117033,0.000006775538,0.00003237521,0.0002651825],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9735759,"threshold_uncertainty_score":0.8593629,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1069024573120856,"score_gpt":0.4167122480531281,"score_spread":0.3098097907410425,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}